| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0057
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-227
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate |
2000-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2003-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2003513027-A |
| titleOfInvention |
Agent and method for diagnosing, imaging and treating atherosclerosis |
| abstract |
(57) [Summary]nThe present invention provides a novel human MabFab cloned by phage display and its use in diagnostics and therapeutics. In particular, the present invention provides a method for analyzing the OxLDL component of an atherosclerotic lesion in vivo and a means for determining the relative lesion. Since this method is based on human Fab rather than mouse Mab, the progress or regression of the disease is monitored at any time. Antibodies are also used for the analysis of in vitro surgical or serum samples for the presence of OxLDL. This antibody may be used as a target therapeutic for atherosclerotic lesions, or may be used as a therapeutic itself. |
| priorityDate |
1999-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |